Cancers

Journal Browser

► Journal Browser

Special Issue Editors

Dr. Patrick Okolo

E-Mail Website
Guest Editor

Chief of Gastroenterology, Rochester Regional Health, Division of Gastroenterology, Rochester General Hospital, Rochester, NY 14621, USA
Interests: gastrointestinal endoscopy; gastrointestinal malignancy; epidemiology

Dr. Chengu Niu

E-Mail Website
Guest Editor

1. Director of Research, Rochester General Hospital, Internal Medicine Residency Program, Rochester General Hospital, Rochester, NY 14621, USA
2. Adjunct Assistant Professor of LECOM, Lake Erie College of Osteopathic Medicine (LECOM), Erie, PA, USA
Interests: gastrointestinal cancer; epidemiology; immunotherapy

Special Issue Information

Dear Colleagues,

This Special Issue, titled "Gastrointestinal Malignancy: Epidemiology and Risk Factors", is dedicated to unveiling cutting-edge research and novel insights in the field of gastrointestinal cancers. It will particularly emphasize emerging trends and technologies in diagnosis and treatment, including advances in molecular markers and genetic risk factors. The Special Issue seeks to present a comprehensive exploration of various gastrointestinal malignancies, delving into their epidemiology and the multifaceted risk factors contributing to their onset and progression. Contributions from global experts will offer a rich tapestry of perspectives, with the aim of significantly impacting clinical practices and public health policies.

Dr. Patrick Okolo
Dr. Chengu Niu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

gastrointestinal cancer
epidemiology
risk factors
molecular markers
genetic factors
therapeutic advancements
prevention strategies
public health
interdisciplinary approaches
clinical impact

Published Papers (2 papers)

Download All Papers

Research

Jump to: Review

15 pages, 1387 KiB

Open AccessArticle

The Use of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus Does Not Increase the Risk of Pancreatic Cancer: A U.S.-Based Cohort Study

by Mark Ayoub, Carol Faris, Tajana Juranovic, Harleen Chela and Ebubekir Daglilar

Cancers 2024, 16(9), 1625; https://doi.org/10.3390/cancers16091625 - 23 Apr 2024

Viewed by 547

Abstract

Background: GLP-1 RAs are widely used for T2DM treatment due to their cardiorenal and metabolic benefits. This study examines the risk of pancreatic cancer with GLP-1 RA use in patients with T2DM. Methods: We analyzed TriNetX’s deidentified research database using the U.S. Collaborative Network comprising 62 healthcare organizations across the U.S.A. Patients with T2DM were split into two cohorts: one receiving GLP-1 RAs, and one not receiving GLP-1 RAs. We excluded patients with known risk factors for pancreatic cancer, including pancreatic cysts, a personal or family history of BRCA1, BRCA2, CDKN2A, KRAS, MEN1, MLH1, MSH2, NOTCH1, PALB2, PMS2, and PRSS1S genes, family history of pancreatic cancer, and VHL syndrome. Using a 1:1 propensity score-matching model based on baseline characteristics and comorbidities, we created comparable cohorts. We then compared the rate of pancreatic cancer between the two cohorts at a 7-year interval. Results: Out of 7,146,015 identified patients with T2DM, 10.3% were on a GLP-1 RA and 89.7% were not. Post-PSM, 721,110 patients were in each group. Patients on GLP-1 RAs had a 0.1% risk compared to a 0.2% risk of pancreatic cancer in the 7-year timeframe. Conclusion: The use of GLP-1 RAs in patients with type 2 diabetes mellitus (T2DM) does not appear to substantially elevate the risk of pancreatic cancer; in fact, it may potentially exert a protective effect. Full article

(This article belongs to the Special Issue Gastrointestinal Malignancy: Epidemiology and Risk Factors)

► Show Figures

Graphical abstract

Review

Jump to: Research

26 pages, 1570 KiB

Open AccessReview

Progress in Biological Research and Treatment of Pseudomyxoma Peritonei

by Xi Li, Guodong Liu and Wei Wu

Cancers 2024, 16(7), 1406; https://doi.org/10.3390/cancers16071406 - 3 Apr 2024

Viewed by 1391

Abstract

Pseudomyxoma peritonei (PMP) is a rare disease characterized by extensive peritoneal implantation and mass secretion of mucus after primary mucinous tumors of the appendix or other organ ruptures. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is currently the preferred treatment, with excellent efficacy and safety, and is associated with breakthrough progress in long-term disease control and prolonged survival. However, the high recurrence rate of PMP is the key challenge in its treatment, which limits the clinical application of multiple rounds of CRS-HIPEC and does not benefit from conventional systemic chemotherapy. Therefore, the development of alternative therapies for patients with refractory or relapsing PMP is critical. The literature related to PMP research progress and treatment was searched in the Web of Science, PubMed, and Google Scholar databases, and a literature review was conducted. The overview of the biological research, treatment status, potential therapeutic strategies, current research limitations, and future directions associated with PMP are presented, focuses on CRS-HIPEC therapy and alternative or combination therapy strategies, and emphasizes the clinical transformation prospects of potential therapeutic strategies such as mucolytic agents and targeted therapy. It provides a theoretical reference for the treatment of PMP and the main directions for future research. Full article

(This article belongs to the Special Issue Gastrointestinal Malignancy: Epidemiology and Risk Factors)

► Show Figures